The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells

Table 2

Effect of L-2 and CIGB-552 on the cell viability in different tumor cell lines.

Tumor cell line	Origin	L-2 IC50 (μM)*	CIGB-552 IC50 (μM)*
H460	Human nonsmall-cell lung cancer	57 ± 6	23 ± 8
H-125	Human nonsmall-cell lung cancer	75 ± 9	42 ± 6
H-82	Human small-cell lung cancer	50 ± 6	15 ± 3
LS174T	Human colon adenocarcinoma	56 ± 3	22 ± 4
MDA-231	Human breast adenocarcinoma	125 ± 3	40 ± 9
PBMC	Human mononuclear cells	234 ± 9	249 ± 6

The peptides were added to 10,000 cells in a range of concentrations from 0 to 200 μM. After 48 hours of incubation, cell viability was determined by SRB (sulforhodamine B, sodium salt) assay. Finally, absorbance was measured at 492 nm, and the IC₅₀ values were calculated from the growth curves.
*Mean ± SD of three determinations. Data were obtained from two different experiments.